Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | NOS1 | P29475 | 5/20 | 0.69 |
| ▸ | NOS3 | P29474 | 4/20 | 0.69 |
| ▸ | NOS2 | P35228 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL22347074 | 1.00 | BLM (1.00) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL18206 | 1.00 | BLM (1.00) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL29483831 | 0.97 | BLM (0.94) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Sulfuric Acid SCHEMBL4106019 | 0.86 | CYP2D6 (0.75) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| SCHEMBL27962429 | 0.84 | KDM4E (0.71) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| SCHEMBL78077 | 0.83 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL30740657 | 0.82 | KDM4E (0.68) | BLMCYP2D6CYP2C19KDM4ENPSR1 | |
| Urea SCHEMBL27606252 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL4633139 | 0.79 | — | — | |
| Iodide SCHEMBL916721 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462497-A | Pyridopyrimidinone Process for the preparation of compounds | 上海皓元医药股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| WO-2024221005-A2 | METHODS FOR INHIBITING RESISTANCE TO IMMUNE BLOCKADE INHIBITOR THERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| CN-118320101-B | Application of iNOS inhibitor in preparation of medicament for treating scleroderma collagen deposition | 天津嘉氏堂科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118320101-A | Application of iNOS inhibitor in preparation of medicament for treating scleroderma collagen deposition | 天津嘉氏堂科技有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117900105-B | High-wear-resistance aluminum alloy shell and preparation process thereof | 东莞市伟峰新材料科技有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118063443-A | Nitrogen-containing heterocyclic diketone compound, intermediate and preparation method thereof | 常州恒邦药业有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-109796414-B | Method for continuously preparing rosuvastatin intermediate by adopting micro-channel modular reaction device | 中国药科大学 | 2022-05-20 | — | — | CN | claimed |
| CN-112755012-A | Application of S-methylisothiouronium sulfate in preparation of anti-influenza virus and escherichia coli co-infection medicine | 福建农林大学 | 2021-05-07 | — | — | CN | claimed |
| EP-1017384-B1 | AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION | ZENTARIS GMBH (DE) | 2004-11-10 | — | — | EP | claimed |
| US-20030181480-A1 | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds | ZENTARIS AG | 2003-09-25 | — | — | US | claimed |
| JP-60123459-A | — | — | None | — | — | JP | disclosed |
| CN-122059854-A | Guanidino cyclohexane derivative and preparation method and application thereof | 安徽益普克医药科技发展有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4244227-B1 | FLUORESCENT SENSORS | UNIV SYDNEY (AU) | 2026-04-22 | — | — | EP | disclosed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4069680-B1 | PROCESS FOR SYNTHESIS OF A 2-(5-ISOXAZOLYL)-PHENOL | FMC CORP (US) | 2026-03-25 | — | — | EP | disclosed |
| US-4024271-A | INHIBITORS OF HISTAMINE ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-17 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | disclosed |
| US-3950333-A | HISTAMINE INHIBITORS, OXYALKYL, THIOALKYL, AMINOALKYL DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-04-13 | — | — | US | disclosed |
| US-3944560-A | BRONCHODILATOR | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | TLR8, MYD88, TLR6 | BLM 3383/4885CYP2D6 4183/4885CYP2C19 4244/4885 |
| US-20030181480-A1 | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds | MTOR, BRAF, MKNK1 | BLM 3436/4885CYP2D6 4743/4885CYP2C19 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.